Ticagrelor is a vital and widely prescribed medication used to prevent blood clots in patients with cardiovascular diseases. However, its potent antiplatelet effect poses a significant risk of uncontrollable, life-threatening bleeding during emergencies, trauma, or urgent surgeries. Currently, clinical practice lacks effective, rapidly acting antidotes to safely neutralize ticagrelor, creating an urgent medical demand for a reliable reversal agent.
In a recent study published in Angewandte Chemie International Edition, a research team led by Prof. TANG Cen and Prof. ZHENG Jiajia from the National Center for Nanoscience and Technology (NCNST) of the Chinese Academy of Sciences (CAS), along with Prof. ZHANG Yinlong from the University of Chinese Academy of Sciences (UCAS), developed a novel counterion-engineered nanoparticle system capable of safely and effectively reversing ticagrelor in vivo.
To address the challenge of creating a stable and bio-compatible intravenous antidote, the researchers employed a precise counterion-engineering strategy. They successfully formulated nanoparticles that exhibit high water stability, allowing for safe intravenous administration. Once injected into the bloodstream, these specially designed nanoparticles act as highly specific microscopic "sponges", rapidly capturing and neutralizing free ticagrelor molecules before they can inhibit platelet function.
The research team thoroughly evaluated the antidote's performance. In vivo experiments demonstrated that the engineered nanoparticles could rapidly and efficiently restore normal platelet aggregation and blood clotting functions in animal models treated with ticagrelor. The administration of these nanoparticles significantly reduced both bleeding time and overall blood loss. Furthermore, the nanoparticles exhibited excellent biosafety, clearing the drug without triggering adverse immune responses or causing unwanted thrombosis.
This innovative approach not only solves a critical clinical challenge associated with ticagrelor but also establishes a versatile platform for designing rapid-reversal agents for other small-molecule therapeutics.
